Position in NERV
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$220,272
New position
Shares Held
39,689
first reported quarter
Ownership
0.083%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#32
of 58 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 98%
None 2%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Invesco Ltd. holds $14,420,023,301 across 296 Biotechnology names. NERV ranks #233 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
8,043,052 | $3,995,225,212 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,940,665 | $2,457,162,245 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
3,754,318 | $1,130,162,341 | |
| 4 | INCY |
Incyte Corp
|
4,080,461 | $462,561,050 | |
| 5 | ARGX |
Argenx SE
|
443,990 | $411,920,598 | |
| 6 | AXSM |
Axsome Therapeutics, Inc.
|
1,671,684 | $409,178,086 | |
| 7 | MRNA |
Moderna, Inc.
|
5,780,299 | $404,794,337 | |
| 8 | LGND |
Ligand Pharmaceuticals Inc
|
1,201,644 | $379,827,645 |
All Filings in NERV
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $220,272 | 39,689 | Shares | Defined | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||